Greig Cephalopolysyndactyly Syndrome

National Organization for Rare Disorders, Inc.

Skip to the navigation


It is possible that the main title of the report Greig Cephalopolysyndactyly Syndrome is not the name you expected. Please check the synonyms listing to find the alternate name(s) and disorder subdivision(s) covered by this report.


  • GCPS
  • Polysyndactyly with Peculiar Skull Shape
  • Polysyndactyly-Dysmorphic Craniofacies, Greig Type
  • Frontodigital Syndrome (obsolete)
  • Hootnick-Holmes Syndrome (obsolete)

Disorder Subdivisions

  • None

General Discussion

Greig cephalopolysyndactyly syndrome (GCPS) is a rare genetic disorder characterized by physical abnormalities affecting the fingers and toes (digits) and the head and facial (craniofacial) area. Characteristic digital features may include extra (supernumerary) fingers and/or toes (polydactyly), webbing and/or fusion of the fingers and/or toes (syndactyly), and/or additional abnormalities. Craniofacial malformations associated with this disorder may include a large and/or unusually shaped skull; a high, prominent forehead (frontal bossing); an abnormally broad nasal bridge; widely spaced eyes (ocular hypertelorism); and/or other physical abnormalities. The range and severity of symptoms may vary greatly from case to case. In most cases, GCPS is inherited as an autosomal dominant trait.


Greig cephalopolysyndactyly syndrome, a rare genetic disorder that is present at birth (congenital), is characterized by abnormalities of the fingers and toes (digits) and the head and facial (craniofacial) area. The range and severity of symptoms vary from individual to individual, with the facial characteristics, in particular, being quite subtle in some cases.

Infants with this disorder exhibit various digital malformations, including extra (supernumerary) fingers and/or toes (polydactyly); webbing or fusion of the fingers and/or toes (syndactyly); abnormally wide thumbs and/or great toes (halluces); and/or split (bifid) end bones of the thumbs and/or halluces (terminal phalanges). Affected infants with supernumerary digits will usually display the additional digit(s) toward the "pinky finger" side of the hand (postaxial polydactyly) and the "big toe" side of the foot (preaxial polydactyly).

Affected infants also exhibit several craniofacial malformations including an abnormally large head (macrocephaly); a high, prominent or protruding forehead (frontal bossing); a broad nasal bridge; and/or widely spaced eyes (ocular hypertelorism). In some cases, the fibrous joints (sutures) between certain bones in the skull may be abnormally wide and may close unusually late in development; on the other hand, in rare cases, certain cranial sutures may close prematurely (craniosynostosis). Such irregular closure of the sutures may cause the head to appear unusually shaped (scaphocephaly or plagiocephaly).

In many individuals with GCPS, additional abnormalities may be present. These may include permanently flexed fingers (camptodactyly), dislocation of the hip, protrusion of a portion of the large intestine through an abnormal opening in the muscular wall that lines the lower abdominal cavity (inguinal hernia), and/or other physical abnormalities. In rare cases, developmental delays and abnormalities affecting the nerve fibers (corpus callosum) that connect the two cerebral hemispheres of the brain may be present.


In most cases, Greig cephalopolysyndactyly syndrome is inherited as an autosomal dominant trait. Genetic diseases are determined by two genes, one received from the father and one from the mother. Dominant genetic disorders occur when only a single copy of an abnormal gene is necessary for the appearance of the disease. The abnormal gene can be inherited from either parent, or can be the result of a new mutation (gene change) in the affected individual. The risk of passing the abnormal gene from affected parent to offspring is 50% for each pregnancy regardless of the sex of the resulting child.

In a small number of cases, the disorder may be due to spontaneous (de novo) genetic changes (mutations) early in embryonic development that occur for unknown reasons (sporadic). In such cases, the disorder is not inherited from the parents.

The gene responsible for Greig cephalopolysyndactyly syndrome, the GLI3 gene, is located on the short arm (p) of chromosome 7 (7p13). Chromosomes, which are present in the nucleus of human cells, carry the genetic information for each individual. Pairs of human chromosomes are numbered from 1 through 22, and an additional 23rd pair of sex chromosomes which include one X and one Y chromosome in males and two X chromosomes in females. Each chromosome has a short arm designated "p" and a long arm designated "q". Chromosomes are further sub-divided into many bands that are numbered. For example, "chromosome 7p13" refers to band 13 on the short arm of chromosome 7. The numbered bands specify the location of the thousands of genes that are present on each chromosome.

Mutations disrupting the normal function (expression) of the GLI3 gene are responsible for the disorder. For example, some cases where Greig cephalopolysyndactyly syndrome was inherited as a dominant trait, the disorder was shown to result from a balanced chromosomal translocation in one of the parents involving chromosome 7p13. A translocation is balanced if pieces of two or more chromosomes break off and trade places, creating an altered but balanced set of chromosomes. If a chromosomal rearrangement is balanced, it is usually harmless to the carrier. However, balanced rearrangements are sometimes associated with a higher risk of abnormal chromosomal development in the carrier's offspring. In addition, in some sporadic cases of GCPS, affected individuals have exhibited missing chromosomal material (deletion) involving 7p13. Therefore, according to the medical literature, deletion and/or reduced expression of the GLI3 gene at chromosome 7p13 is thought to lead to GCPS.

Affected Populations

Greig cephalopolysyndactyly syndrome (GCPS) is an extremely rare genetic disorder that is present at birth (congenital) and affects males and females in equal numbers. There have been over 50 cases of this disorder reported in the medical literature. However, because some affected individuals may exhibit few and/or mild symptoms, they may never be diagnosed with the disorder. Therefore, it is difficult to determine the true frequency of GCPS in the general population.

Standard Therapies


Greig cephalopolysyndactyly syndrome (GCPS) is usually diagnosed at birth based upon a thorough clinical evaluation; identification of characteristic physical findings; and specialized imaging procedures, including X-rays and computed tomography (CT) scanning. In some cases, GCPS may be detected before birth (prenatally) by observing the presence of extra digits (polydactyly) and an enlarged skull (macrocephaly) during ultrasound imaging. During ultrasonography, reflected sound waves create images of the developing fetus.

X-rays and CT scanning may be used to detect and reveal the extent of bone fusion in severe cases of syndactyly. In many cases of GCPS, X-ray studies may also reveal abnormally advanced bone age.


The treatment of GCPS is directed toward the specific symptoms apparent in each individual. Treatment may require the efforts of a team of specialists who may need to systematically and comprehensively plan an affected child's treatment. Such specialists may include pediatricians, specialists who diagnose and treat skeletal disorders (orthopedists), orthopedic and plastic surgeons, physical and occupational therapists, and/or other health care professionals.

Specific therapies for the treatment of this disorder are symptomatic and supportive. In some cases, surgery may be performed to correct digital and/or craniofacial abnormalities. Genetic counseling will be of benefit for affected individuals and their families.

Investigational Therapies

Information on current clinical trials is posted on the Internet at All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.

For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:

Tollfree: (800) 411-1222

TTY: (866) 411-1010


For information about clinical trials sponsored by private sources, contact:



Grzeschik KH. Greig Cephalopolysyndactyly Syndrome. In: NORD Guide to Rare Disorders. Lippincott Williams & Wilkins. Philadelphia, PA. 2003:201.

Jones KL., ed. Smith's Recognizable Patterns of Human Malformation. 5th ed. Philadelphia, PA: W. B. Saunders Co: 1997:426.

Gorlin RJ, et al., eds. Syndromes of the Head and Neck, 3rd ed. New York, NY: Oxford University Press; 1990:799-800.

Buyce ML., ed. Birth Defects Encyclopedia. Dover, MA: Blackwell Scientific Publications; For: The Center for Birth Defects Information Services Inc; 1990:1402.


Johnston JJ, et al. Molecular and clinical aspects of Greig cephalopolysyndactyly and Pallister-Hall syndromes: robust phenotype predication from the type and position of GLI3 mutations. Am J Med Genet. 2005;76:609-22.

Johnston JJ, et al. Clinical and molecular delineation of the Greig cephalopolysyndactyly contiguous gene deletion syndrome and its distinction from acrocallosal syndrome. Am J Med Genet. 2003;123:236-42.

Debeer P, et al. Variable phenotype in Greig cephalopolysyndactyly syndrome: clinical and radiological findings in 4 independent families and 3 sporadic cases with identified GLI3 mutations. Am J Med Genet. 2003;120:49.58.

Ausems MG, et al. Greig cephalopolysyndactyly syndrome in a large family: a comparison of the clinical signs with those described in the literature. Clin Dysmorphol. 1994;3:21-30.

Vortkamp A, et al. Isolation of a yeast artificial chromosome contig spanning the Greig cephalopolysyndactyly syndrome (GCPS) gene region. Genomics. 1994;22:563-58.

Fryns JP, et al. Apparent Greig cephalopolysyndactyly and sinus node disease. Am J Med Genet. 1993;45:38-40.

Vortkamp A, et al. GLI3 zinc-finger gene interrupted by translocations in Greig syndrome families. Nature. 1991;352:539-40.

Gemmill RM, et al. A 2.5-mb physical map within 3p21.1 spans the breakpoint associated with Greig cephalopolysyndactyly syndrome. Genomics. 1991;11:93-102.

Drabkin H, et al. Regional and physical mapping studies characterizing the Greig polysyndactyly 3;7 chromosome translocation, t(3;7)(p21.1;p13). Genomics. 1989;4:518-29.

Pliskin ME, et al. The occurrence of a fibro-osseous lesion and multiple dental anomalies in a patient with the Greig cephalopolysyndactyly syndrome. Oral Surg Oral Med Oral Pathol. 1988;66:475-9.

Gollop TR, et al. The Greig cephalopolysyndactyly syndrome: report of a family and review of the literature. Am J Med Genet. 1985;22:59-68.

Kunze J, et al. Greig cephalopolysyndactyly syndrome. Report of a sporadic case. Helv Paediatr Acta. 1985;40:489-495.

Merlob P, et al. Greig's syndrome. Neonatal radiologic manifestations. J Radiol. 1984;65:187-9.

Baraitser M, et al. Greig cephalopolysyndactyly: report of 13 affected individuals in three families. Clin Genet. 1983;24:257-65.

Merlob P, et al. A newborn infant with craniofacial dysmorphism and polysyndactyly (Greig's syndrome). Acta Paediatr Scand. 1981;70:275-7.

Fryns JP, et al. The Greig polysyndactyly craniofacial dysmorphism syndrome: variable expression in a family. Eur J Pediatr. 1981;136:217-20.

Duncan PA, et al. Greig cephalopolysyndactyly syndrome. Am J Dis Child. 1979;133:818-21.

Fryns JP, et al. The Greig polysyndactyly-craniofacial dysmorphism syndrome. Eur J Pediatr. 1977;126:283-7.


McKusick VA, ed. Online Mendelian Inheritance in Man (OMIM). Baltimore. MD: The Johns Hopkins University; Entry No:175700; Last Update:3/18/2005. Available at: Accessed On: April 29, 2005.

Biesecker LE. Updated: Oct. 7, 2004. Greig Cephalopolysyndactyly Syndrome. In.: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2004. Available at Accessed: April 29, 2005.


Children's Craniofacial Association

13140 Coit Road

Suite 517

Dallas, TX 75240


Tel: (214)570-9099

Fax: (214)570-8811

Tel: (800)535-3643



FACES: The National Craniofacial Association

PO Box 11082

Chattanooga, TN 37401

Tel: (423)266-1632

Fax: (423)267-3124

Tel: (800)332-2373




PO Box 751112

Las Vegas, NV 89136


Tel: (702)769-9264

Fax: (702)341-5351

Tel: (888)486-1209




333 East 30th Street, Lobby Unit

New York, NY 10016

Tel: (212)263-6656

Fax: (212)263-7534



Genetic and Rare Diseases (GARD) Information Center

PO Box 8126

Gaithersburg, MD 20898-8126

Tel: (301)251-4925

Fax: (301)251-4911

Tel: (888)205-2311

TDD: (888)205-3223


Madisons Foundation

PO Box 241956

Los Angeles, CA 90024

Tel: (310)264-0826

Fax: (310)264-4766



For a Complete Report

This is an abstract of a report from the National Organization for Rare Disorders, Inc.® (NORD). Cigna members can access the complete report by logging into For non-Cigna members, a copy of the complete report can be obtained for a small fee by visiting the NORD website. The complete report contains additional information including symptoms, causes, affected population, related disorders, standard and investigational treatments (if available), and references from medical literature. For a full-text version of this topic, see